Product Overview
[Drug Name]
Generic Name: Fenofibrate Sustained-Release Capsules
Trade Name: Libifei
English Name: Fenofibrate Sustained-Release Capsules
Chinese Pinyin: Feinuobeite Huanshi Jiaonang
[Ingredients]
The main ingredient of this product is fenofibrate. Its chemical name is isopropyl 2-methyl-2-[4-(4-chlorobenzoyl)phenoxy]propionate. Molecular formula: C20H21ClO4. Molecular weight: 360.84
[Properties]
This product is a hard capsule containing off-white pellets.
[Indications] This product is a lipid-regulating drug, suitable for hypercholesterolemia and hypertriglyceridemia that cannot be controlled with appropriate and regular dietary therapy.
[Dosage and Administration]
Adults: Oral: 0.25g (one tablet) once daily.
[Adverse Reactions]
A small number of patients may experience gastrointestinal discomfort, belching, or transient elevations in serum transaminases and blood urea nitrogen (BUN) after taking this medication. Occasionally, they may experience dry mouth, decreased appetite, increased bowel movements, abdominal distension, rash, headache, dizziness, and fatigue. Rarely, they may experience myositis, myalgia, and significant elevations in blood creatine phosphokinase (CPK).
[Contraindications]
1. Patients with severe renal impairment. 2. Patients with primary biliary cirrhosis, long-term liver impairment, or preexisting gallbladder disease. 3. Patients with hypersensitivity to this product.
[Precautions]
1. Patients with renal impairment should have their dose reduced based on renal creatinine clearance. 2. Diagnostic Interference: This product may increase platelet count, BUN, transaminases, and serum calcium; and may decrease blood alkaline phosphatase, gamma-glutamyl transpeptidase, and bilirubin. 3. Regular checks during medication: 1. Complete blood count and platelet count; 2. Liver function tests; 3. Blood cholesterol, triglycerides, or low-density and very-low-density lipoproteins.
[Use in Special Populations]
Precautions for Children: Contraindicated in children.
Precautions for Pregnancy and Lactation: Contraindicated in pregnant and lactating women.
Precautions for Elderly: The dosage of this product should be appropriately reduced for elderly patients.
[Drug Interactions]
It has an enhanced anticoagulant effect. The dosage of concomitant oral anticoagulants should be halved and subsequently adjusted based on test results.
[Pharmacological Actions]
This is a clofibrate-type lipid regulator that inhibits cholesterol and triglyceride synthesis and increases steroid excretion. It also reduces plasma fibrinogen levels and platelet viscosity, reducing thrombus formation.
Storage: Store in a sealed, light-proof container.
Specifications: 0.25g x 10 tablets
Packaging: Box
Expiration Date: 36 months
Approval Number: National Medicine Standard H19990303
Manufacturer: Shanghai Aifa Pharmaceutical Co., Ltd.
